Literature DB >> 1752440

The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.

C D Southgate1, M R Green.   

Abstract

The Tat protein of human immunodeficiency virus type 1 (HIV-1) activates transcription following binding to nascent trans-activation response (TAR) RNA downstream of the transcription start site. Because Tat functions when bound to RNA, and in a position-dependent manner, it has been proposed that Tat works by a novel mechanism. Here, we perform a series of protein fusion experiments that reveal striking similarities between Tat and conventional cellular activators. Most significantly, we demonstrate that Tat can function when bound to upstream promoter DNA. This activity depends on a region within Tat that is also required for Tat to function when bound to TAR RNA. In contrast, the arginine-rich region of Tat, which is required for binding to TAR RNA, is dispensable for the function of DNA-bound Tat. When bound either to RNA or DNA Tat activity requires cooperation with promoter-bound cellular transcription factors. Finally, we show that Tat and a strong acidic activator stimulate transcription to comparable levels. On the basis of these and other results we suggest that Tat and acidic activators act on a similar step in the transcription process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752440     DOI: 10.1101/gad.5.12b.2496

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  107 in total

1.  Evolutionary conserved mechanism of transcriptional repression by even-skipped.

Authors:  L M McKay; B Carpenter; S G Roberts
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

2.  Formation of Tap/NXT1 heterodimers activates Tap-dependent nuclear mRNA export by enhancing recruitment to nuclear pore complexes.

Authors:  Heather L Wiegand; Glen A Coburn; Yan Zeng; Yibin Kang; Hal P Bogerd; Bryan R Cullen
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes.

Authors:  Ran Taube; Xin Lin; Dan Irwin; Koh Fujinaga; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

4.  An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein.

Authors:  J Yang; H P Bogerd; S Peng; H Wiegand; R Truant; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

5.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 6.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

7.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Genetic analysis indicates that the human foamy virus Bel-1 protein contains a transcription activation domain of the acidic class.

Authors:  W S Blair; H Bogerd; B R Cullen
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1.

Authors:  B Majello; P De Luca; G Hagen; G Suske; L Lania
Journal:  Nucleic Acids Res       Date:  1994-11-25       Impact factor: 16.971

10.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.